Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Patients undergoing major abdominal surgery are at highest risk for developing Postoperative
Ileus (POI), occurring in nearly all cases. Signs and symptoms of POI may include abdominal
distention and bloating, persistent abdominal pain; nausea and/or vomiting; variable
reduction of bowel sounds; delayed passage of or inability to pass flatus or stool; and
inability to tolerate a solid diet. This study will test the ability of alvimopan 12 mg given
30 to 90 minutes before the scheduled start of surgery to hasten the recovery of GI function
in patients having partial small or large bowel resections.